Gerard J. Michel, CEO, highlighted, "Quarterly revenue reached $24.2 million, an increase of over 20% compared to the first quarter of 2025, reflecting continued strong adoption. U.S. sales of HEPZATO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback